Industry Program

Industry Program

Industry symposium sessions will offer pertinent data on the latest scientific information and developments from the industry. Hear from leading experts on the latest advances in nephrology practices, therapies, services, and technologies. There are up to five industry sessions per day included in your WCN registration. Industry symposia are also open-access!

The program will run daily between April 16-19, 2021 from 08:00-14:00 Eastern Daylight Time to reach viewers in North & South America. For European and African participants, the program can be viewed between 14:00-20:00 Central European Time. For time zones without convenient access to the live program (Asian and Australian participants) sessions will be available for on-demand viewing.

Detailed programs will be available here in February.

Friday, April 16

11:00 – 12:00 EDT

Saturday, April 17

11:00 – 12:00 EDT

Sunday, April 18

11:00 – 12:00 EDT

Monday, April 19

08:00 – 09:00 EDT

Slot available
Slot available

Slot available
Slot available
Slot available
Slot available
Slot available
Slot available
Last updated: February 26, 2021

Industry Symposia Program (Friday, April 16, 2021)

  • Contemporary concepts in ADPKD: Innovations in clinical practice and novel disease mechanisms
  • Organizer:  Genzyme
  • Room: Room 5
  • Time: 11:00 – 12:00
  • Chair(s):Merlis, Ronli (United States)
  • Schedule:
    Time Title Speaker
    11:00 – 11:02 Welcome and Introduction Lanktree, Matthew (Canada)
    11:02 – 11:10 Insights into ADPKD from genetic studies Lanktree, Matthew (Canada)
    11:10 – 11:35 Clinical practice update and case presentations in ADPKD Pei, York (Canada)
    11:35 – 11:50 Novel disease mechanisms in ADPKD Maski, Manish (United States)
    11:50 – 12:00 Q&A All Faculty (Canada)

  • Why Target the Mucosal Immune System of the Gut to Treat IgA Nephropathy?
  • Organizer: Callitidas
  • Room: Room 2
  • Time: 11:00 – 12:00
  • Chair(s): Udell, Andrew (Sweden)
  • Schedule:
    Title Speaker
    Welcome and introductions BARRATT, Jonathan
    Targets for new drug development in IgAN Rovin, Brad
    The rationale for targeting the mucosal immune system in IgAN BARRATT, Jonathan
    Clinical experience of targeting the Peyer’s patches in IgAN Lafayette, Richard
    Q&A BARRATT, Jonathan

  • Nonsteroidal MRAs: A new chapter for the management of CKD in T2D
  • Organizer: Bayer
  • Room: Room 3
  • Time: 11:00 – 12:00
  • Chair(s): Erdmann, Stephanie (Germany)
  • Schedule:
    Time Title Speaker
    11:00 – 11:05 Welcome and introductions Pecoits-Filho, Roberto
    11:05 – 11:25 Inflammation and fibrosis as a driver of CKD progression: An opportunity for intervention? Cherney, David
    11:25 – 11:45 Impact of MR antagonism in CKD in T2D: Lessons from the FIDELIO-DKD trial Bakris, George
    11:45 – 11:55 Q&A All Faculty
    11:55 – 12:00 Summary & Close All Faculty

  • Proteinuria Treatment Targets in Glomerular Disease: Providing Insights into Clinical Outcomes
  • Organizer: Travere
  • Room: Room 1
  • Time: 11:00 – 12:00
  • Chair(s): Hammer, Bernice (United States)
  • Schedule:
    Time Title Speaker
    11:00 – 11:30 Introduction and setting the scene Barbour, Sean (Canada)
    Proteinuria targets in FSGS Mariani, Laura (United States)
    Proteinuria targets in IgAN Barbour, Sean (Canada)
    Proteinuria as surrogate endpoint for regulatory approval of novel therapeutics in glomerular disease Carroll, Kevin J. (United States)
    Close, Q&A and integrated polling Barbour, Sean (Canada)

Industry Symposia Program (Saturday, April 17, 2021)

  • The Challenge of Slowing Diabetic Kidney Disease Progression And Reducing Cardiovascular Risk: Recent Advances and Novel Strategies
  • Organizer: Cardiometabolic Health Congress
  • Room: Room 5
  • Time: 11:00 – 12:00
  • Chair(s): McAdams, Karin (United States)
  • Schedule:
    Time Title Speaker
    Introduction, Background and Future of DKD Bakris, George L. (United States)
    New Perspectives in the Management of CKD in T2D: the Eemerging Role of MRAs Agarwal, Rajiv (United States)
    Effect of Finerenone on CKD Outcomes in T2D Bakris, George L. (United States)
    Finerenone and Cardiovascular Outcomes Filippatos, Gerasimos (Greece)
    Panel Discussion, Q&A and Closing All Faculty

  • SGLT2 inhibitors: The next step to optimal care in CKD
  • Organizer: AstraZeneca – Change IME
  • Room: Room 1
  • Time: 11:00 – 12:00
  • Chair(s): Yu, Alice (United Kingdom)
  • Schedule:
    Time Title Speaker
    11:00 – 11:30 Welcome and Introduction Tuttle, Katherine (United States)
    Impacting clinical practice – SGLT2 inhibitors in CKD Correa-Rotter, Ricardo (Mexico)
    How SGLT2 inhibitors fit in the CKD management framework Cherney, David (Canada)
    Initiating SGLT2 inhibitors – the cardiologist’s experience Jhund, Pardeep (United Kingdom)
    Close and Q&A All Faculty

  • Kidney itch: what’s new and what to do
  • Organizer: Connect2 CME
  • Room: Room 4
  • Time: 11:00 – 12:00
  • Chair(s): Watty-Miller, Mandi (United Kingdom)
  • Schedule:
    Title Speaker
    Welcome and Introduction Rayner, Hugh (United Kingdom)
    Sukul, Nidhi (United Kingdom)
    A patient’s experience Rigatto, Claudio (United Kingdom)
    The burden and impact of kidney itch worldwide Rayner, Nidhi (United Kingdom)
    Why do kidney patients itch? Rigatto, Claudio (United Kingdom)
    Retrieving data. Wait a few seconds and try to cut or copy again. Rayner, Hugh (United Kingdom)

  • A discussion with KDIGO: Individual optimization of management of CKD patients with diabetes and CVD comorbidities
  • Organizer: Boheringer/Lilly-KDIGO
  • Room: Room 3
  • Time: 11:00 – 12:00
  • Chair(s): Danielle Green (United States)
  • Schedule:
    Title Speaker
    Welcome and Introductions Wanner, Christoph (Germany)
    SGLT2 inhibitors and GLP-1 receptor agonists: Different classes, different modes of kidney protection Lambers Heerspink, Hiddo (The Netherlands)
    Case 1: Kidney benefits associated with current pharmacotherapies in patients with CKD and diabetes Rossing, Peter (Demnark)
    Case 2: Cardiovascular benefits associated with current pharmacotherapies in patients with CKD and diabetes Michos, Erin (United States)
    Panel discussion All Faculty

Industry Symposia Program (Sunday, April 18, 2021)

  • Treating Anemia of CKD: Real-World Clinical Experience with HIP-PH Inhibitors
  • Organizer: AstraZeneca – Change IME
  • Room: Room 1
  • Time: 11:00 – 12:00
  • Chair(s): Yu, Alice (United Kingdom)
  • Schedule:
    Time Title Speaker
    Welcome and Introduction Levin, Adeera (Canada)
    Hao, Chaun-Ming (China)
    HIF-PH inhibitors: Evidence from clinical trials Provenzano, Robert (United States)
    My clinical experience with HIF-PH inhibitors Hao, Chaun-Ming (China)
    Chairs’ summary and Q&A Levin, Adeera (Canada)

  • Fabry Disease: An Unexpected Cause of Renal Disease
  • Organizer: Excel CME
  • Room: Room 2
  • Time: 11:00 – 12:00
  • Chair(s): Rebull, Grace (United States)
  • Schedule:
    Time Title Speaker
    11:00 – 11:30 Overview of Fabry Disease: Classic vs Non-Classic Mauer, Michael (United States)
    Renal Manifestations: Biomarkers, Clinical, Kidney Pathology, Evaluation
    11:30 – 12:00 Evidence-based Long-term Disease Management Therapy ORTIZ, ALBERTO (Spain)
    Current and Emerging Therapies and Treatment Recommendations
    12:00 – 12:30 Q&A and Closing All Faculty

Industry Symposia Program (Monday, April 19, 2021)

  • Examining Primary Hyperoxaluria Type 1 and Results from ILLUMINATE-A and ILLUMINATE-B Clinical Trials
  • Organizer: Alnylam
  • Room: Room 2
  • Time: 08:00 – 09:00
  • Chair(s): Yu, Alice (United Kingdom)
  • Schedule:
    Time Title Speaker
    08:00 – 08:45 Examining Primary Hyperoxaluria Type 1 and Results from ILLUMINATE-A and ILLUMINATE-B Clinical Trials Saland, Jeffrey (United States)
    08:45 – 09:00 Questions and answers Saland, Jeffrey (United States)

  • New Insights in Alport Syndrome and Genetic Testing
  • Organizer: Reata
  • Room: Room 1
  • Time: 08:00 – 09:00
  • Chair(s): Dolly Livingston (United States)
  • Schedule:
    Time Title Speaker
    08:00 – 08:10 How Alport Syndrome is Diagnosed and Triaged Torra, Roser (Spain)
    08:10 – 08:20 Classification/Disease Subtypes Torra, Roser (Spain)
    08:20 – 08:30 Genetics underlying the Disease and Prognosis Knebelmann, Bertrand (France)
    08:30 – 08:45 Case Studies in Alport Syndrome Knebelmann, Bertrand (France)
    08:45 – 09:00 Questions and Answers Torra, Roser – Knebelmann, Bertrand